Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Actelion re-enters talks with J&J, sidelining Sanofi

Published 21/12/2016, 18:48
© Reuters. The company's logo is seen at the headquarters of Swiss biotech company Actelion in Allschwil
ATLN
-
SASY
-
SHP
-
PFE
-
JNJ
-

By John Revill and Ludwig Burger

ZURICH/FRANKFURT (Reuters) - Swiss biotech company Actelion (S:ATLN) has turned back to prospective bidder Johnson & Johnson (N:JNJ) for exclusive talks about a "strategic transaction", in an about-turn that appears to sideline rival suitor Sanofi (PA:SASY).

Actelion said in a brief statement on Wednesday it was in exclusive negotiations with the U.S. healthcare giant but that there could be "no assurance any transaction will result from these discussions", declining to comment further.

J&J confirmed the talks in a separate statement.

The announcement could dash the hopes of French drugmaker Sanofi, which sources have said has been circling Actelion after J&J a little over a week ago said it had ended discussions with Actelion.

Sanofi has been trying to broaden its drug line-up as its key diabetes business comes under pressure.

The French company has signalled it remained keen to make a takeover deal after being trumped in August by Pfizer's (N:PFE) $14 billion bid for U.S. cancer drug company Medivation.

Sanofi declined to comment on Wednesday.

Actelion had a market value of 23.2 billion Swiss francs (18.3 billion pounds) at Wednesday's closing price of 215 Swiss francs in Switzerland.

U.S. shares in Actelion rose 11 percent after the announcement. J&J shares were down 0.3 percent at 1815 GMT.

Actelion had told J&J before initial talks collapsed last week that it was confident it could attract an offer significantly higher than the approximately 250 Swiss francs per share the U.S. company had offered, one person familiar with the matter said.

There were also disagreements about the proposed deal's structure, the person added at the time.

Actelion co-founder and Chief Executive Jean-Paul Clozel has fended off previous takeover attempts, including a reported takeover approach by Shire (L:SHP) last year and an activist campaign in 2011 by U.S. hedge fund Elliott Advisors.

© Reuters. The company's logo is seen at the headquarters of Swiss biotech company Actelion in Allschwil

Acquiring the Swiss biotech firm would boost J&J's drug pipeline and diversify its prospects. J&J's biggest product, the arthritis drug Remicade, faces cheaper competition from Pfizer (N:PFE).

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.